Company intelligence / Profile preview

Nalpropion Pharmaceuticals

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Nalpropion Pharmaceuticals commercialized CONTRAVE (naltrexone HCl and bupropion HCl extended release), an FDA-approved small molecule drug for obesity/weight loss. CONTRAVE became the most prescribed branded obesity medication in the U.S. since June 2015, with strong real-world utilization but limited clinical innovation compared to newer GLP-1 drugs. The drug has a boxed warning for suicidal thoughts and is contraindicated in certain conditions.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Pernix Therapeutics (investor and management partner, 2018-2019)

Beyond the preview

Go deeper on Nalpropion Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nalpropion Pharmaceuticals.

Explore the full profile